Prosecution Insights
Last updated: November 18, 2026
Application No. 18/728,965

NEW STEREORETENTIVE RUTHENIUM COMPLEXES, METHOD OF THEIR PREPARATION, INTERMEDIATES USED IN THIS METHOD AND USE OF NEW STEREORETENTIVE RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS

Non-Final OA §102
Filed
Jul 15, 2024
Priority
Jan 17, 2022 — PL PL440147 +1 more
Examiner
KETCHAM, HANNAH ELIZABETH
Art Unit
1742
Tech Center
1700 — Chemical & Materials Engineering
Assignee
UNIWERSYTET WARSZAWSKI
OA Round
1 (Non-Final)
Grant Probability
Favorable
1-2
OA Rounds

Examiner Intelligence

Grants only 0% of cases
0%
Career Allowance Rate
0 granted / 0 resolved
-65.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
37 currently pending
Career history
23
Total Applications
across all art units
This examiner has no resolved cases yet (career too new); statute-level performance unavailable. The Grant Probability card shows Tech Center averages instead.

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 8 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tasuku et al. WO 2004/ 020549 A1. Tasuku teaches a Pt(bpy)(qdt) (bpy = 2,2’-bipyridine; qdt = quinoxaline-2,3-dithiolate) complex (Figure 20, see below), Pt(4dmbpy)(qdt) (4dmbpy = 4,4’-dimethyl-2,2’-bipyridine) (Figure 22), Pt(5dmbpy)(qdt) (5dmbpy = 5,5’-dimethyl-2,2’-bipyridine) (Figure 23), Pt(dbbpy)(qdt) (dbbpy = 4,4’-ditertbutyl-2,2’-bipyridine) (Figure 24). The backbone of this structure corresponds to structure 3a of in the instant claims. The Pt is a divalent cation, E is at least one heteroatom selected from a group comprising O, S, Se, N, and P, which are substituted with a chelating system which forms a substituted heteroaromatic system of 10 carbons, and is substituted with C1-C12 alkyls in the case of 4dmbpy, 5dmpy, and dbbpy. In this case the R1 and R2 form an unsubstituted cyclic system. PNG media_image1.png 114 290 media_image1.png Greyscale Allowable Subject Matter Claims 9-10 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Regarding claims 9 and 10, the further limitation of the cation as M2+ Zn, Cu, Mg, Ca, or M+ as Li, Na, K, Cs, Cu teaches away from Tasuku et al., which only teaches Pt2+. Claims 1-7, 13-22 are allowed. Muller et al. (Müller DS, Baslé O, Mauduit M. A tutorial review of stereoretentive olefin metathesis based on ruthenium dithiolate catalysts. Beilstein J Org Chem. 2018; 14, 2999-3010.) teaches the formation of complex Ru-2 (Figure 1; see below). The complex meets the majority of the structural limitation of claim 1, except benzene ring bonded to the dithio group. The benzene ring does not meet the claim limitation, since it is not a pyrazine ring. PNG media_image2.png 215 238 media_image2.png Greyscale Verpoort et al. (US 20150367338 A1) teaches Grubbs’ 2nd generation catalyst and the Hoveyda catalyst, which are both commercial Ru olefin metathesis catalysts (paragraphs [0015], [0016]; see below). Both the Grubbs’ catalyst and Hoveyda catalyst contain the majority of the structure limitation required by the claims, except for the dithiopyrazine ring. PNG media_image3.png 143 138 media_image3.png Greyscale PNG media_image4.png 158 140 media_image4.png Greyscale Herron et al. (US 20210291155 A1) teaches a metathesis catalyst that teaches the mahroity of the structural limitations as required by the instant claims (paragraphs [0057]-[066]; see below), but does not teach the pyrazine ring. The M is a group 8 transition metal, typically Ru, L1 = a carbene; L2 = a neutral electron donor ligand; n = 0 or 1; m = 0, 1, or 2; R = unsubstituted hydrocarbyl, substituted hydro carbyl, unsubstituted heteroatom containing hydrocarbyl, or substituted heteroatom containing hydrocarbyl; generally R is unsubstituted C1-C10 alkyl, substituted C1-C10 alkyl, unsubstituted C3-C8 cycloalkyl, substituted C3-C8 cycloalkyl, unsubstituted C5-C24 aryl or substituted C5-C24 aryl, typically R is methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, or phenyl; R1 and R2 = independently hydrogen, unsubstituted hydrocarbyl, substituted hydrocarbyl, unsubstituted heteroatom containing hydrocarbyl, or substituted heteroatom containing hydrocarbyl or typically, R1 is hydrogen and R2 is phenyl, substituted phenyl or substituted 1-propenyl ; or R1 and R2 are linked together to form an optionally substituted indenylidene; X4 and X5 = O or S; RX, RY, RW, Rz = independently hydrogen, halogen, unsubstituted hydrocarbyl, substituted hydrocarbyl, unsubstituted heteroatom containing hydrocarbyl, or substituted heteroatom containing hydrocarbyl (paragraphs [0057]-[066]). PNG media_image5.png 149 204 media_image5.png Greyscale Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to HANNAH E KETCHAM whose telephone number is (571)270-0742. The examiner can normally be reached Monday-Friday 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christina Johnson can be reached at (571) 272-1176. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /H.E.K./Examiner, Art Unit 1742 /CHRISTINA A JOHNSON/Supervisory Patent Examiner, Art Unit 1742
Read full office action

Prosecution Timeline

Jul 15, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
Grant Probability
Low
PTA Risk
Based on 0 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month